PCM
IMVT icon

Peregrine Capital Management’s Immunovant IMVT Stock Holding History

Peregrine Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-291,456
Closed -$3.08M – 339
2021
Q2 		$3.08M Sell
291,456
-15,547
-5% -$217K 0.06% 256
2021
Q1 		$4.92M Buy
307,003
+142,386
+86% +$3.75M 0.09% 255
2020
Q4 		$7.6M Sell
164,617
-15,048
-8% -$696K 0.14% 244
2020
Q3 		$6.32M Buy
+179,665
New +$5.4M 0.17% 193

Other funds holding IMVT

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peregrine Capital Management's IMVT Position: Q3 2021 in Review

Peregrine Capital Management sold out of Immunovant (IMVT) in Q3 2021, closing a stake of 291,456 shares — an estimated $3.08M sold.

Peregrine Capital Management first reported a position in IMVT in Q3 2020 and held it in 4 quarters. The position peaked at $7.6M in Q4 2020. 119 funds tracked by Wall St. Rank hold IMVT as of Q3 2021.

  • Peregrine Capital Management reported no remaining Immunovant position as of Q3 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 291,456 Immunovant shares in Q3 2021, an estimated $3.08M.
  • Peregrine Capital Management first reported a position in Immunovant in Q3 2020 and held it in 4 quarters.
  • Peregrine Capital Management's Immunovant position peaked at $7.6M in Q4 2020.
  • 119 funds tracked by Wall St. Rank held Immunovant as of Q3 2021.

Based on Peregrine Capital Management's 13F filing for Q3 2021, filed 2 Nov 2021.